Kimball Genetics Inc has launched a warfarin sensitivity DNA test for research and investigational purposes. The test determines the presence of specific variations in the CYP2C9 and VKORC1 genes that confer sensitivity to warfarin. The DNA test identifies patients who are sensitive to warfarin and, therefore, require a lower dose to achieve their target levels and may be at increased risk for bleeding complications.
The FDA Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Sciences has recommended testing for genetic variations in patients requiring warfarin therapy. This recommendation is likely to be reflected on the drug's label soon. The company expects the DNA test to be available for routine clinical use sometime this year.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs